Biodesix, Inc. (NASDAQ: BDSX) shares fell Friday. The Louisville, Colo-based company, a leading diagnostics solutions concern, announced the publication of the largest lung nodule biomarker clinical ...
(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever ...
Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.
SAN ANTONIO, March 17, 2026--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in ...
bioAffinity Technologies Inc BIAF shares are trading higher on Tuesday morning. The move follows the release of a new clinical case study. The study highlights the benefits of adding CyPath Lung to ...
Imagine you go to the healthcare provider because you have a bad cough, or maybe you fell and hurt your ribs.
The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...
Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...
Biodesix is focused on the large, underserved lung nodule market with five Medicare-covered tests and estimates ~6 million new nodules annually; it’s expanding into targeted primary care referral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results